Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 11:44 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–45 of 45 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: HCTZ + Amlodipine Clear all

Conditions: Hypertension
Interventions: aliskiren; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 493 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Stage 2 Systolic Hypertension
Interventions: valsartan, amlodipine, HCTZ, Losartan, HCTZ followed by valsartan, amlodipine, HCTZ; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 488 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Hypertension, Mild Cognitive Impairment
Interventions: Candesartan, Lisinopril; Drug
Lead sponsor: Emory University; Other
Eligibility: 55 Years and older
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Atherosclerosis, Cardiovascular Diseases, Hypercholesterolemia, Hypertension, Diabetes Mellitus, Type 2, Diabetes Mellitus, Coronary Disease
Interventions: Anti-hyperglycemic Agents, Anti-hypertensive Agents, Blinded fenofibrate or placebo plus simvastatin; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 40 Years to 79 Years
Enrollment: 10,251 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2012
U.S. locations: 6
States / cities: Minneapolis, Minnesota • New York, New York • Winston-Salem, North Carolina + 3 more

Conditions: Hypertension
Interventions: amlodipine and olmesartan, losartan and HCTZ; Drug
Lead sponsor: InVasc Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Tucker, Georgia

Conditions: Hypertension
Interventions: Aliskiren, Amlodipine, Hydrochlorothiazide; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 556 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Santa Fe, New Mexico

Conditions: Hypertension, Plasma Renin Activity
Interventions: Hydrochlorothiazide, Lisinopril, Amlodipine, metoprolol, lisinopril/hydrochlorothiazide; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Hypertension
Interventions: Aliskiren, Amlodipine, Hydrochlorothiazide (HCTZ), Placebo; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 1,191 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Hypertension
Interventions: Olmesartan medoxomil, Amlodipine, Hydrochlorothiazide; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 2,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 228
States / cities: Birmingham, Alabama • Columbiana, Alabama • Gulf Shores, Alabama + 225 more

Conditions: Hypertension
Interventions: olmesartan, hydrochlorothiazide, amlodipine, hydrochlorothiazide (HCTZ) or olmesartan; Drug
Lead sponsor: The Louis & Rachel Rudin Foundation; Other
Eligibility: 40 Years to 85 Years
Enrollment: 185 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 5
States / cities: The Bronx, New York

Conditions: Hypertension
Interventions: olmesartan medoxomil + hydrochlorothiazide + amlodipine + hydralazine if necessary to control blood pressure, atenolol+ hydrochlorothiazide + amlodipine + hydralazine if necessary to control blood pressure; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Metabolic Syndrome, Lipotoxicity
Interventions: Valsartan, Hydrochlorothiazide; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 50 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Hypertension
Interventions: Olmesartan medoxomil, Hydroclorothiazide, Benazepril, Amlodipine; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 20
States / cities: Mobile, Alabama • Long Beach, California • Los Angeles, California + 17 more

Conditions: Cardiovascular Diseases, Heart Diseases, Hypertension, Coronary Disease, Myocardial Infarction
Interventions: Chlorthalidone, Lisinopril, Amlodipine, Doxazosin; Drug
Lead sponsor: Donna Arnett, 257-5678; Other
Eligibility: 55 Years and older
Enrollment: 37,939 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2005
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Hypertension, Metabolic Syndrome
Interventions: Aliskerin/Valsartan and Rampiril; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Type 2 Diabetes, Hypertension
Interventions: Amlodipine, amlodipine / olmesartan medoxomil combination, Hydrochlorothiazide; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 207 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 21
States / cities: Los Angeles, California • Sylmar, California • Tustin, California + 18 more

Conditions: Hypertension
Interventions: LCZ696, Olmesartan, LCZ696 matching placebo, Olmesartan matching placebo, amlodipine, hydrochlorothiazide; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 60 Years and older
Enrollment: 454 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 11
States / cities: Clearwater, Florida • Chicago, Illinois • Baltimore, Maryland + 8 more

Conditions: Essential Hypertension
Interventions: Aliskiren, Amlodipine, Hydrochlorothiazide; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 564 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hypertension, COVID
Interventions: ACEI/ARB, Non-ACEI/ARB, ACEI, ARB; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 22,213 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Hypertension, Type 2 Diabetes Mellitus
Interventions: Nebivolol, Metoprolol ER, HCTZ; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 231 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 62
States / cities: Athens, Alabama • Huntsville, Alabama • Bell Gardens, California + 54 more

Conditions: Hypertension
Interventions: Aliskiren Hydrochlorothiazide (HCTZ): 8 weeks, Amlodipine: 8 weeks; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 332 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: East Hanover, New Jersey

Search by objective public record fields.

A Clinical Study to Compare Combination of Aliskiren+ HCTZ to Irbesartan+ HCTZ or Amlodipine+ HCTZ or HCTZ Alone in Obese Hypertensive Not Responsive to HCTZ 25 mg

Valsartan/Amlodipine As Compared to Losartan Treatment in Stage 2 Systolic Hypertension

CAndesartan vs LIsinopril Effects on the BRain

Action to Control Cardiovascular Risk in Diabetes (ACCORD)

Changes in Endothelial Function and Biomarkers in African Americans (AA) With Metabolic Syndrome

An Assessment of Long Term Safety of the Combination of Aliskiren / Amlodipine in Patients With High Blood Pressure

A Pilot Study of Plasma Renin Activity Guided vs Generic Combination Therapy for Hypertension

Efficacy and Safety of Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Moderate-severe Hypertension

Safety and Efficacy Study of a Triple Combination Therapy in Subjects With Hypertension

Renin Profiling in Selection of Initial Antihypertensive Drug

Vascular Improvement With Olmesartan Medoxomil Study

Regression of Fatty Heart by Valsartan Therapy

Treatment of High Blood Pressure Using Olmesartan With Hydrochlorothiazide Compared to an ACE Inhibitor With a Calcium Channel Blocker

Genetics of Hypertension Associated Treatments (GenHAT)

The Study of Novel Dual Renin Angiotensin Aldosterone System (RAAS) Blockade; Valsartan/Aliskiren in African American Patients With Hypertension and the Metabolic Syndrome

18 Week Study Evaluating Safety and Efficacy of Olmesartan, Amlodipine, and Hydrochlorothiazide, in Type 2 Diabetics

Study of the Safety and Efficacy of LCZ696 on Arterial Stiffness in Elderly Patients With Hypertension

A Long Term Safety Study to Test the Combination of Aliskiren/ Amlodipine / Hydrochlorothiazide in Participants With Essential Hypertension

ACEI or ARB and COVID-19 Severity and Mortality in US Veterans

Study of the Glycemic Effects of Nebivolol Compared With Metoprolol and HCTZ in Diabetic Hypertensive Patients

Blood Pressure Lowering of Aliskiren Hydrochlorothiazide (HCTZ) Versus Amlodipine in Stage 2 Hypertension in African Americans